Certain factors may increase the likelihood of experiencing bloating on GLP-1 therapy, including: Pre-existing gastrointestinal conditions such as irritable bowel syndrome (IBS), functional dyspepsia, or small intestinal bacterial overgrowth (SIBO) Rapid dose escalation without adequate titration periods Dietary factors , particularly high intake of fermentable carbohydrates (FODMAPs), fatty foods, or carbonated beverages Concurrent medications that affect gastrointestinal motility Patients should be aware that GLP-1 receptor agonists have been associated with more serious gastrointestinal adverse effects, including pancreatitis (inflammation of the pancreas) and gallbladder disease
Aging cell 2020;19, e13188, doi:10.1111/acel.13188
It can also be valuable for patients who want medical treatment that is structured and monitored rather than trend-based
Hepatology 60 , 20992108 (2014)
As a clinical nutritionist specializing in weight management, I see this all the time
examined 11 studies involving patients over the age of 65 receiving GLP-1 receptor agonist treatments
